Open-label placebo treatment to reduce appetite/overeating in obese children: an app-assisted approach

• Conditions: E66.04; obesity

• Registration Number: DRKS00029251
• Lead Sponsor: niversität Graz

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-06-07
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

BMI > 90th percentile

Exclusion Criteria

• Medication (e.g., antidepressants, appetite suppressants)
• Somatic diseases (e.g., neurological disorders, digestive problems)
• Mental disorders (e.g., ADHD, eating disorders)
• Puberty (menstruation, pubic hair, voice fluctuation, breast-growth, acne)

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Comparison of appetite reduction between the 4 weeks with vs. without OLP (Open-Label-Placebo)

Secondary Outcome Measures

Name	Time	Method
Comparison of body weight at the end of 4 weeks with vs. without OLP (Open-Label-Placebo) treatment